What is the recommended KLOW Blend (BPC-157 + TB-500 + GHK-Cu + KPV) dosage?

KLOW Blend (BPC-157 + TB-500 + GHK-Cu + KPV) dosing varies by experience level. Beginners typically start at 2000mcg daily, moderate users at 4000mcg daily, and aggressive protocols use 6000mcg daily.

How do you reconstitute KLOW Blend (BPC-157 + TB-500 + GHK-Cu + KPV)?

KLOW Blend (BPC-157 + TB-500 + GHK-Cu + KPV) typically comes in 80mg vials. Add 3mL of bacteriostatic water to the vial. Use our free calculator for exact syringe units based on your desired dose.

What is the half-life of KLOW Blend (BPC-157 + TB-500 + GHK-Cu + KPV)?

The half-life of KLOW Blend (BPC-157 + TB-500 + GHK-Cu + KPV) is Varies by component (15 min–4 hours). This determines how frequently you need to dose for consistent blood levels.

KLOW Blend (BPC-157 + TB-500 + GHK-Cu + KPV) Dosage Guide & Calculator

Benefits

Reduces systemic inflammation through NF-kB pathway suppression via KPV

Accelerates gut mucosal healing — especially useful during GLP-1 therapy

Supports skin elasticity and collagen production during rapid weight loss

Promotes tendon and ligament repair via BPC-157 and TB-500

Enhances wound healing and tissue remodeling through multiple pathways

Preserves muscle and connective tissue integrity during caloric restriction

Supports body recomposition when combined with exercise and diet protocols

About KLOW Blend (BPC-157 + TB-500 + GHK-Cu + KPV)

The KLOW Protocol is a pre-blended four-peptide stack that combines GHK-Cu, BPC-157, TB-500, and KPV into a single 80mg vial. Originally developed as a recovery and tissue repair blend, it's gained traction in the weight management space because of its ability to support body recomposition during aggressive fat loss phases. Each component targets a different biological pathway. GHK-Cu (50mg per vial) is a copper-binding tripeptide first isolated by Loren Pickart in 1973. It drives collagen and elastin synthesis, supports skin tightening during weight loss, and activates antioxidant gene expression. BPC-157 (10mg per vial) is a 15-amino-acid fragment derived from human gastric juice. Predrag Sikiric's research group in Zagreb has published over 100 preclinical studies showing it accelerates tendon, ligament, and gut mucosal healing — all of which matter during caloric restriction when tissue repair slows. TB-500 (10mg per vial) is a synthetic fragment of thymosin beta-4. Goldstein and Kleinman's early work demonstrated its role in cell migration, angiogenesis, and wound repair. It helps maintain muscle integrity during aggressive cutting phases. KPV (10mg per vial) is a C-terminal tripeptide from alpha-melanocyte stimulating hormone. Bhatt et al. (2008) showed it enters intestinal epithelial cells via the PepT1 transporter and suppresses NF-kB inflammatory signaling at nanomolar concentrations. This makes KPV especially useful for calming gut inflammation triggered by dietary changes or GLP-1 agonist side effects. The blend doesn't directly burn fat. Instead, it creates a protective internal environment — healing the gut lining, reducing systemic inflammation, preserving connective tissue, and supporting skin elasticity — that allows users to sustain more aggressive weight loss protocols with fewer side effects and less tissue breakdown.

Who Should Consider KLOW Blend (BPC-157 + TB-500 + GHK-Cu + KPV)

Individuals on GLP-1 agonists seeking gut protection and tissue support
People in active weight loss phases wanting to preserve skin and connective tissue
Athletes recovering from injuries while maintaining caloric deficits
Adults with chronic low-grade inflammation affecting body composition
Post-surgical patients needing accelerated tissue repair
Those experiencing GI side effects from weight loss medications

How KLOW Blend (BPC-157 + TB-500 + GHK-Cu + KPV) Works

KLOW works through four distinct but complementary signaling pathways. GHK-Cu delivers bioavailable copper into dermal and connective tissue, activating fibroblast proliferation and upregulating genes for collagen I, collagen III, elastin, and glycosaminoglycans. Pickart's gene expression studies found GHK-Cu modulates over 4,000 human genes, including antioxidant enzymes like superoxide dismutase. BPC-157 interacts with the nitric oxide system and upregulates growth hormone receptor expression. Sikiric's research shows it promotes angiogenesis through VEGF pathway activation, accelerates tendon outgrowth via FAK-paxillin signaling, and protects endothelial function. It also modulates dopamine and serotonin systems, which may help stabilize mood during caloric restriction. TB-500 promotes actin polymerization and cell migration. It sequesters G-actin monomers, preventing premature polymerization and allowing orderly cytoskeletal reorganization at wound sites. This is the basis for its tissue repair effects — Goldstein's group showed thymosin beta-4 increased keratinocyte migration 2- to 3-fold at concentrations as low as 10pg. KPV enters cells via the PepT1 transporter expressed on intestinal epithelial and immune cells. Once inside, it stabilizes IkB-alpha, preventing NF-kB nuclear translocation and suppressing downstream production of IL-8 and other pro-inflammatory cytokines. Dalmasso et al. (2008) demonstrated that oral KPV reduced colitis incidence in DSS and TNBS animal models.

What to Expect

Week 1-2

Subtle improvements in energy and recovery. Some users notice reduced joint stiffness and improved sleep quality. Gut comfort may improve, especially if pairing with a GLP-1 agonist. This is the initial assessment period — stay at the beginner dose.

Week 3-4

Anti-inflammatory effects become noticeable. Reduced bloating and improved digestion. Minor soft tissue aches begin to resolve. Skin hydration starts to improve as GHK-Cu collagen pathways activate.

Week 5-7

Peak healing response. Tendon and ligament repair accelerates. Skin elasticity visibly improves, particularly in areas affected by weight loss. Systemic inflammation markers (if tracked via bloodwork) may show measurable decline.

Week 8-10

Full benefits reached. Skin firmness and tone at their best for the cycle. Gut lining integrity well-supported. Users on GLP-1 therapy often report fewer GI side effects by this point. Evaluate results and prepare for the off-cycle.

Week 11-14

off cycle

Four-week break. BPC-157 and TB-500 healing effects persist as tissue remodeling continues. Collagen benefits from GHK-Cu have a slow turnover and remain visible. Reassess before starting another cycle.

Dosing Protocol

Level	Dose / Injection	Frequency
Beginner	2mg	Daily
Moderate	4mg	Daily
Aggressive	6mg	Daily

Note: Four-peptide recovery and body recomposition stack in a fixed 80mg vial: GHK-Cu (50mg) + BPC-157 (10mg) + TB-500 (10mg) + KPV (10mg). Doses shown are the combined total in mcg per injection. Start at the beginner tier for 2 weeks before increasing. Reconstitute with 3mL bacteriostatic water for a concentration of ~26.7mg/mL. Rotate injection sites between the abdomen and outer thigh. Many users pair KLOW with a GLP-1 agonist for weight loss — the KLOW blend helps preserve tissue integrity, reduce inflammation, and support gut healing during caloric restriction. Pin once daily, preferably in the evening.

How to Inject KLOW Blend (BPC-157 + TB-500 + GHK-Cu + KPV)

Reconstitute the 80mg vial with 3mL bacteriostatic water. Swirl gently — don't shake. This gives a total concentration of approximately 26.7mg/mL. Draw the desired dose using a 29-31 gauge insulin syringe. Inject subcutaneously into the abdomen (rotating left and right of the navel) or outer thigh. Pinch a fold of skin, insert the needle at a 45-degree angle, inject slowly, and hold for 5 seconds before withdrawing. Administer once daily, preferably in the evening to align with overnight tissue repair cycles. Keep a brief log of injection sites to ensure proper rotation. Store the reconstituted vial upright in the refrigerator between uses.

Cycling Protocol

On Period

10 weeks

Off Period

4 weeks

Run daily injections for 8-12 weeks. Weeks 1-4 serve as a loading phase at the beginner dose. Increase to moderate dosing by week 3-4 if well tolerated. Take 4 weeks off before repeating. Most users run 2-3 cycles per year. When pairing with GLP-1 agonists, start KLOW 1-2 weeks before the GLP-1 to establish a baseline of gut and tissue support.

Pharmacokinetics

Half-Life

2h

Bioavailability

SC: estimated 70-90% across components; GHK-Cu ~85%, BPC-157 ~variable, TB-500 ~high, KPV ~moderate

Tmax

GHK-Cu: ~30min; BPC-157: ~15-30min; TB-500: ~1-2h; KPV: ~30-60min

Data Confidence

low

Source: Weighted estimate across four components. BPC-157 has the shortest plasma half-life (~15 min per Sikiric et al.), followed by KPV (~1-2h), GHK-Cu (~2-4h), and TB-500 (~2-3h). The dominant component by mass is GHK-Cu (62.5% of the blend), which anchors the effective duration. No unified PK data exists for the combined four-peptide formulation.

Pharmacokinetics — Active Dose Over Time

Loading the interactive decay curve.

Side Effects

KLOW is generally well-tolerated. The most common side effect is injection site irritation — redness, mild swelling, or itching that resolves within an hour. GHK-Cu's copper content can cause transient skin flushing in some users. BPC-157 may cause mild nausea, dizziness, or headache, particularly at higher doses. TB-500 has been associated with temporary lethargy and mild headache during loading phases. KPV side effects are rare in published literature. Some users report increased fatigue during the first week as the body adjusts. A small number of people experience mild GI discomfort including bloating or changes in bowel frequency. Because GHK-Cu promotes angiogenesis and BPC-157 upregulates growth factor signaling, anyone with a history of cancer should avoid this blend entirely. There's no human clinical trial data on the combined four-peptide formulation, so long-term safety remains unknown. All side effect profiles are extrapolated from individual component research.

Contraindications

Pregnancy or breastfeeding
Active cancer or history of cancer (GHK-Cu promotes angiogenesis; BPC-157 upregulates growth factors — both may support tumor growth)
Wilson's disease or copper metabolism disorders (GHK-Cu delivers bioavailable copper)
Active autoimmune conditions in flare (TB-500 and BPC-157 modulate immune signaling)
Known allergy to copper or any component peptide
Children under 18 years of age

Drug Interactions

Copper supplements — risk of copper overload when combined with GHK-Cu
Anticoagulants and blood thinners — BPC-157 and GHK-Cu promote angiogenesis and may affect clotting dynamics
NSAIDs — BPC-157 interacts with the nitric oxide and prostaglandin systems; combined use may alter anti-inflammatory balance
Immunosuppressants — KPV and TB-500 modulate immune pathways; may reduce or amplify immunosuppressive effects
GLP-1 receptor agonists — generally used together intentionally but monitor for additive GI effects during the first 2 weeks
Corticosteroids — TB-500 and BPC-157 may partially counteract steroid-induced tissue atrophy, but combined use is unstudied
High-dose zinc supplements (>50mg/day) — competitive inhibition at copper transport sites can reduce GHK-Cu uptake